Bolt Biotherapeutics, Inc. (BOLT)

NCM – Real Time Price. Currency in USD

4.78

+0.08 (1.70%)

At close: May 12, 2026, 4:00 PM EDT

12.03.2026

Bolt Biotherapeutics, Inc. (BOLT) Reports Q4 Loss, Tops Revenue Estimates

Bolt Biotherapeutics, Inc. (BOLT) came out with a quarterly loss of $3.84 per share versus the Zacks Consensus Estimate of a loss of $4.3. This compares to a loss of $7.6 per share a year ago.

12.03.2026

Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update

REDWOOD CITY, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the fourth quarter and full-year ended December 31, 2025, and provided a business update.

24.02.2026

Bolt Biotherapeutics to Participate in Upcoming March Conferences

REDWOOD CITY, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced that management will participate in two upcoming conferences in March:

12.11.2025

Bolt Biotherapeutics, Inc. (BOLT) Reports Q3 Loss, Beats Revenue Estimates

Bolt Biotherapeutics, Inc. (BOLT) came out with a quarterly loss of $3.72 per share versus the Zacks Consensus Estimate of a loss of $5.07. This compares to a loss of $8 per share a year ago.

12.11.2025

Bolt Biotherapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Initial clinical data for BDC-4182 Phase 1 dose escalation study expected in 3Q 2026 Cash balance of $38.8 million as of September 30, 2025 anticipated to fund key milestones into 2027 REDWOOD CITY, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the third quarter ended September 30, 2025, and provided a business update.

04.11.2025

Bolt Biotherapeutics, Inc. (BOLT) Expected to Beat Earnings Estimates: Should You Buy?

Bolt Biotherapeutics (BOLT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Videos

No Data

There is no data to display

Press releases

12.03.2026

Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update

24.02.2026

Bolt Biotherapeutics to Participate in Upcoming March Conferences

12.11.2025

Bolt Biotherapeutics, Inc. (BOLT)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Bolt Biotherapeutics, Inc. (BOLT)

Bolt Biotherapeutics, Inc. (BOLT) Reports Q4 Loss, Tops Revenue Estimates

Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update

Bolt Biotherapeutics to Participate in Upcoming March Conferences

Bolt Biotherapeutics, Inc. (BOLT) Reports Q3 Loss, Beats Revenue Estimates

Bolt Biotherapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Bolt Biotherapeutics, Inc. (BOLT) Expected to Beat Earnings Estimates: Should You Buy?

Videos

No Data

Press releases

Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update

Bolt Biotherapeutics to Participate in Upcoming March Conferences

Bolt Biotherapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Bolt Biotherapeutics, Inc. (BOLT) Reports Q4 Loss, Tops Revenue Estimates

Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update

Bolt Biotherapeutics to Participate in Upcoming March Conferences

Bolt Biotherapeutics, Inc. (BOLT) Reports Q3 Loss, Beats Revenue Estimates

Bolt Biotherapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Bolt Biotherapeutics, Inc. (BOLT) Expected to Beat Earnings Estimates: Should You Buy?

Videos

No Data

Press releases

Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update

Bolt Biotherapeutics to Participate in Upcoming March Conferences

Bolt Biotherapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Search stocks

Bolt Biotherapeutics, Inc. (BOLT)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Bolt Biotherapeutics, Inc. (BOLT)

Bolt Biotherapeutics, Inc. (BOLT) Reports Q4 Loss, Tops Revenue Estimates

Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update

Bolt Biotherapeutics to Participate in Upcoming March Conferences

Bolt Biotherapeutics, Inc. (BOLT) Reports Q3 Loss, Beats Revenue Estimates

Bolt Biotherapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Bolt Biotherapeutics, Inc. (BOLT) Expected to Beat Earnings Estimates: Should You Buy?

Videos

No Data

Press releases

Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update

Bolt Biotherapeutics to Participate in Upcoming March Conferences

Bolt Biotherapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Bolt Biotherapeutics, Inc. (BOLT) Reports Q4 Loss, Tops Revenue Estimates

Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update

Bolt Biotherapeutics to Participate in Upcoming March Conferences

Bolt Biotherapeutics, Inc. (BOLT) Reports Q3 Loss, Beats Revenue Estimates

Bolt Biotherapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Bolt Biotherapeutics, Inc. (BOLT) Expected to Beat Earnings Estimates: Should You Buy?

Videos

No Data

Press releases

Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update

Bolt Biotherapeutics to Participate in Upcoming March Conferences

Bolt Biotherapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update